INTRODUCTION
Multiple myeloma (MM) is the second most common hematological malignancy. MM results from a clonal proliferation of malignant plasma cells in the bone marrow (BM) and may stem from a premalignant condition termed as monoclonal gammopathy of undetermined significance. Despite therapeutic advances, MM is still incurable because of chemotherapeutic resistance due to the interaction between MM cells and the BM milieu. 1, 2 Within the BM, MM cells uncouple bone resorption and bone formation, resulting in severe osteolysis in B80% of patients, 3, 4 which is critical for tumor progression, 5 and is associated to unfavorable prognosis. 6 Therefore, MM cell homing to the BM and proliferation within this organ is a critical step in the pathogenesis of the disease. 6, 7 The Stromal Cell-Derived Factor-1 (SDF-1 or CXCL12) and its receptor, CXCR4, induce tumor cells localization to the BM and promote osteolysis. Consistently, CXCR4 expression is correlated with poor prognosis, 8 while elevated SDF-1 serum levels are associated with increased osteolytic disease. 9 SDF-1 is secreted by bone endothelium, BM stromal cells and immature osteoblasts. 10 MM cell lines and primary malignant plasma cells also secrete SDF-1, which in turn enhances the proliferation of MM cells. 11 SDF-1 engages CXCR4 on MM cells favoring their recruitment to the BM by affecting migration, [12] [13] [14] adhesion and extravasation. 15 SDF-1 is also a regulator of bone resorption, as it controls the migration of osteoclast precursors and holds them within the bone environment. 11 Accordingly, an independent study on both patients' and cultured cells clearly shows a strong correlation between CXCR4/SDF-1 activation and MM-related bone disease. 9 Recently, Notch has been proposed as a promising therapeutic target in MM, basing on its deregulation in malignant cells. 16 Notch receptors are trans-membrane proteins activated by specific ligands (Jagged-1, -2 and Delta-Like-1, -3, -4). 17 Ligand binding leads to the g-secretase-mediated release of the intracellular domain which then translocates to the nucleus and binds the CSL transcription factor, activating target genes involved in different biological processes. 16 MM cells activate Notch signaling through homotypic interactions, as they simultaneously express Notch1, 18 Notch2, 19, 20 Notch3 21 and the ligands Jagged1 18, 20 and Jagged2. 19, 22, 23 Notch1 and Jagged1 expression is associated with tumor progression from monoclonal gammopathy of undetermined significance to MM. 18 Of note, elevated Notch1 levels are associated with diffuse BM infiltration. 18 Jagged2 has a central role in MM due to its over-expression in MM patients as a result of promoter hypomethylation, 22 constitutive acetylation 19 or overexpression of the Jagged2 specific ubiquitin-ligase Skeletrophin. 23 The outcomes of Notch activation in MM cells are inhibition of apoptosis, resistance to chemotherapeutics and increased osteolysis. 16, [24] [25] [26] On the basis of these evidences and on the recently reported Notch ability to regulate specific chemokine receptors, 25, [27] [28] [29] [30] we hypothesized that the CXCR4/SDF-1 axis could participate in the Notch signaling network.
Here we study the interaction between Notch receptors and the CXCR4/SDF-1 axis, focusing on the biological outcomes in MM cells. In addition, we describe the effects of an anti-Notch treatment on BM invasion by human MM cells in NOD/SCID xenografts.
MATERIALS AND METHODS

Cells and treatments
Human MM cell lines OPM-2, KMS-12 and RPMI-8226 were a kind gift of Prof Carmelo Carlo-Stella. Cells were maintained in complete RPMI-1640 medium supplemented with 10% V/V fetal bovine serum at 3 Â 10 5 cells/ ml. GSI-XII was administered to MM cells at the final concentration of 6 mM. Recombinant human SDF-1 (Peprotech, Rocky Hill, NJ, USA) was given at 0.5 mg/ml. SAHM1 (Merck Ltd, Nottingham, UK) was reconstituted in DMSO (10 mM) and administered at 10, 20 or 40 mM. SDF-1-blocking antibody and matched isotypic control were from R&D Systems, Inc, Minneapolis, MN, USA, and were used as described. 31 The CXCR4 inhibitor AMD3100 32 was from Sigma-Aldrich, Milano, Italy.
Quantitative real-time PCR Total RNA was isolated using NucleoSpin RNA II Kit (Macherey-Nagel, Duren, Germany). Complementary DNA was prepared form 1 mg total RNA through MMLV reverse transcriptase (RT, Promega Italia, Italy), then quantitative PCR was performed using the GoTaq q-PCR Master Mix (Promega Italia s.r.l., Milano, Italy) and the 7900HT platform (PE Applied Biosystem-Life Technologies Corporation, Foster City, CA, USA) as previously described. 25 Data are presented as the relative expression (control ¼ 1), calculated by the 2 À DDCt formula, where DDCt ¼ DCt GSI-XIIDCt DMSO and DCt ¼ Ct GENE -Ct GAPDH . Primers were as follows:
Chemotaxis assay KMS-12, OPM-2 and RPMI-8226 were treated with 6 mM GSI-XII for 48 h, then allowed to migrate in response to 100 ng/ml SDF-1 (Peprotech, Rocky Hill, NJ, USA) using 8 mM-pore polycarbonate Transwell supports (Corning, Amsterdam, the Netherlands) as described. 25 Cell migration was reported as migration index (MI), which is the ratio between the number of cells migrated in response to SDF-1 and the number of cells migrated in the absence of chemokine.
ELISA assay for SDF-1
Flat-bottom 96-well polycarbonate plates were coated at 4 1C overnight with 50 ml/well cell culture supernatants diluted 1:1 in carbonate coating buffer (0.1 M Na 2 CO 3 , 0.1 M NaHCO 3 , pH¼ 9.5). Standard curves were obtained by serially diluting purified recombinant human SDF-1 (R&D Systems) in coating buffer. After removing diluted supernatants or standards and blocking with PBS supplemented with 1% W/V BSA for 1 h at room temperature, plates were incubated with mouse anti-human SDF-1 (2 mg/ml in PBS, 50 ml/well, Abcam, Cambridge, MA, USA) for 1 h at room temperature. Then, the plates were washed twice with phosphatebuffered saline (PBS) containing 0.025% V/V Tween-20 (300 ml/well) and incubated with anti-mouse HRP-labeled secondary antibody (0.2 mg/ml in PBS, 50 ml/well; Abcam) for 1 h at room temperature. The plates were washed three times with PBS containing 0.025% V/V Tween-20 (300 ml/well), then the TMB colorimetric substrate (Thermo Fisher Scientific, Waltham, MA, USA) was added, and after 5 min the 450 nm optical density was measured using a Victor-2 microplate reader (PerkinElmer, Waltham, MA, USA). All samples were run in triplicates.
Flow cytometry
To measure CXCR4 expression, cells were incubated with 1% V/V fetal bovine serum in PBS for 10 min at room temperature, centrifuged and incubated for 30 min at 4 1C in the dark with APC-conjugated mouse antihuman CXCR4 or isotype-matched control (Decton Dickinson, Milano, Italy). For SDF-1 intracellular staining, cells were harvested and resuspended in 0.1 ml PBS containing 1% BSA and 0.1% NaN 3 , then fixed by adding one volume of 4% formaldehyde in PBS, mixed thoroughly and incubated for 20 min at room temperature. After washing, cells were permeabilized in 0.5% saponin þ 0.5% bovine serum albumin in PBS for 10 min at room temperature, centrifuged and resuspended in 20 ml permeabilization buffer containing 2 ml APC-conjugated mouse antihuman SDF-1 or isotype matched control (R&D Systems). After 1-h incubation at 4 1C in the dark, cells were washed once with 0.3 ml permeabilization buffer, then twice with 0.3 ml PBS before acquisition. For the detection of active Notch1, cells were washed in PBS, fixed with 100% icecold methanol and permeabilized with PBS supplemented with 0.5% W/V BSA and 0.5% V/V Tween-20. Cells were then labeled at room temperature using rabbit anti-Val 1744 antibody (Cell Signlaing, Milano, Italy; 1:15) for 30 min. After washing in PBS, the PE-conjugated anti-rabbit antibody was added (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Cells were processed using the Cytomics FC500 software (Beckman Coulter s.r.l., Milano, Italy).
Apoptosis assay
Cells were harvested and stained with Annexin V-FITC Apoptosis Detection Kit (Bender Medsystems GmbH, Vienna, Austria) according to the manufacture's specifications. Cells were processed using the Cytomics FC500 software (Beckman Coulter s.r.l., Milano, Italy).
Cell cycle analysis
Cells were resuspended in GM buffer (PBS supplemented with 1 mg/ml D-glucose, 0.2 mg/ml EDTA, 2% V/V fetal bovine serum), fixed with ethanol (70% V/V), and incubated for 10 min at 4 1C. After washing with PBS, cells were incubated in PBS supplemented with 25 mg/mL RNAse-A, 25 mg/mL Propidium Iodide, and 0,004% V/V NP-40. After 1 h incubation at 37 1C in the dark, cells were analyzed by flow-cytometry.
MTT Assay
Cells were incubated with 0.5 mg/ml MTT (Sigma-Aldrich) in the dark at 37 1C and 5% CO 2 for 4 h. After adding two volumes of DMSO, the optical density at 540 nm was measured.
Transfections and plasmids
Extracellular domain-deleted Notch1 (DE-N1) and intracellular Notch1 (ICN1) constructs were as previously described. 33, 34 For the reporter assays, the thymidine kinase promoter-driven Renilla luciferase (TK-pRL) and the firefly luciferase-encoding pGL3 plasmids were from Promega (Promega Italia s.r.l., Milano, Italy). The plasmid carrying the CXCR4-promoter contained the sequence between À 310 bp and þ 53 bp form CXCR4 start codon. Six micrograms of total DNA were used for electroporation. DNA amounts were as follows: 0.690 mg ICN1/pcDNA3.1, 5.1 mg pGL3/ CXCR4-promoter-pGL3, and 0.21 mg TK-pRL. Cells were harvested and resuspended (10 7 /ml) in BTXpress electroporation buffer (BTX, Holliston, MA, USA). One hundred microliters of this suspension were mixed with 6 mg DNA, then transferred into a 2.0 mm-gap cuvette (BTX). Electroporation was performed using 150 V and 950 mF. All analyses were performed 48 h after transfection. pcDNA3.1 and pCS2 þ mock plasmids were from Invitrogen (Invitrogen Life Technologies Italia, Italy).
Reporter assay
The dual luciferase assay was performed according to the manufacturer's directions (Dual-Luciferase Reporter Assay System, Promega).
NOD/SCID xenografts
A total of 15 NOD/SCID mice (NOD.CB17-Prkdc scid /J strain from The Jackson Laboratory, Bar Harbor, Maine, USA.) were used. All mice received 325 cGy/mouse 137 Cs-irradiation. 24 h later, 10 animals were given intravenous injections (in two consecutive days) containing 10 6 OPM-2 cells in the lateral tail vein in 100 ml PBS. Five control mice, which did not receive myeloma cells, served as negative controls, and were given PBS alone. Ten days after cell injection, MM-injected mice were divided in to two groups: group 1 (five animals) received GSI-XII, while group 2 (five animals) received equal volumes of DMSO (GSI-XII vehicle). GSI-XII was given daily for 30 days via intraperitoneal injection (5 mg/g per day, 50 ml injection). 35 Three of the tumor-free mice received DMSO treatment, while the two of them were given GSI-XII. Mice were checked daily for signs of excessive discomfort, and sacrificed 30 days after tumor cells administration. On day 19 after tumor injection, a total of three mice died: two MM-bearing animals (one of the DMSO-and one of the GSIgroup) and one tumor-free mouse (DMSO group). They were excluded from the following post-mortem analyses. Bones, liver, spleen, kidneys and lungs were collected for flow-cytometry evaluations as we have described. 36 All experimental procedures were in accordance to the protocol approved by the Institutional Animal Care and Usage Committee of the Texas Tech University HSC, School of Medicine (Lubbock, TX, USA).
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Immunohistochemistry
Following formalin-fixation, decalcification with 10% EDTA (pH ¼ 8), and de-hydration in ethanol, femurs were included in paraffin, then cut in consecutive, 3mm-thick sections. After deparaffinization in xylene and rehydration (100%-95%-70%-50% ethanol scale), slides were placed for 10 min in distilled water, then incubated for 20 min at 98 1C in 1 mM EDTA (pH ¼ 8.0). After blocking with PBS þ 1% V/V fetal bovine serum (1 h at room temperature), sections were permeabilized with 0.1% saponin in PBS for 2 h at room temperature, then the anti-k and anti-l chain antibody mix (Santa Cruz Biotechnology) was added (diluted 1:50 in PBS þ 0.1% saponin), and allowed to incubate overnight at room temperature. Sections were rinsed twice in PBS þ 0.05% Tween-20, then endogenous peroxidase was blocked with 1% H 2 O 2 in PBS for 10 min. After rinsing three times with PBS þ 0.05% Tween-20 for 2 min, the polyvalent HRP Polymer Detection System (Abcam) was used to detect primary antibodies following the manufacturer's directions. Staining was evidenced after 5 min incubation with 1 Â DAB solution (Abcam) followed by a 10-min-incubation in distilled water. Pictures of hematoxylin counter-stained sections were taken by using a Leica microscope equipped with a DFC280 camera (Leica Microsystems, Buffalo Grove, IL, USA), and analyzed with the LAS v2.8.1 software (Leica).
Statistical analysis
Data are represented as mean ± 95% confidence interval of independent experiments performed in triplicate. Two-tailed Student's t-test was used to compare the means of normally distributed values. Analysis of variance was performed by Tukey's post-test. Po0.05 indicated statistical significance. RESULTS g-secretase blockade inhibits MM cell viability by affecting cell cycle progression and apoptosis rate KMS-12, OPM-2 and RPMI-8226 cell lines underwent a 48-h treatment with 6mM GSI-XII or equal amount of drug vehicle (DMSO, 0.015% V/V). Cell viability was calculated by a standard Trypan-blue staining: Figure 1a shows that GSI-XII reduced the number of viable cells compared with DMSO (average reduction was 67%:72% in KMS-12, 54% in OPM-2 and 77% in RPMI-8226). Cell cycle distribution analysis (Figure 2b ) revealed that GSI-XII significantly increased the G 2 /M phase by 40% on average ( þ 44.2% in KMS-12, þ 39.6% in OPM-2 and þ 36.0% in RPMI-8226). G 2 /M phase increment matched with a comparable reduction in both G 0 /G 1 and S phases (Figure 1b) . GSI-XII treatment resulted in higher frequency of Annexin-V þ cells compared with controls ( Figure 1c) . Comparable results-albeit at a minor extentwere obtained on OPM-2 cells following treatment with another g-secretase inhibitor, DAPT (40 and 80 mM; not shown).
Notch inhibition results in downregulation of CXCR4 and its ligand SDF-1 at the transcriptional and protein levels Quantitative PCR (Figure 2a ) was performed to evaluate variations in HES-1, CXCR4 and SDF-1 levels following GSI-XII treatment. Transcripts fold change was calculated as reported 25 to compare GSI-XII-treated with control cells. GSI-XII significantly reduced the levels of the HES-1 transcript in all the tested cell lines, indicating that the Notch pathway was effectively inhibited. This inhibition correlated with CXCR4 and SDF-1 downregulation (Figure 2a) . Figure 2b displays flow-cytometry analysis for the detection of CXCR4 þ cells after 48-h treatment with DMSO or GSI-XII: in accordance with quantitative PCR results, a more dramatic reduction in CXCR4 at the cell surface was seen in KMS-12 and OPM-2 compared with RPMI-8226 cells.
The 48 h-conditioned culture medium was used to measure variations in SDF-1 protein secreted by DMSO-or GSI-XII-treated cells: direct enzyme-linked immunosorbent assay (Figure 2c ) showed that blockade of Notch pathway produced a significant decrease in secreted SDF-1, with more relevant effects seen in KMS-12 and OPM-2 (B40% reduction) compared with RPMI-8226 (30% decrease). These results were confirmed by flow-cytometric analysis of viable cells expressing intracellular SDF-1 (Figure 2d ; about 50% reduction in SDF-1 þ cells).
Notch pathway inhibition hampers CXCR4-driven chemotactic response As our results showed that blocking the Notch pathway by g-secretase inhibition caused a significant reduction in CXCR4 protein located at the cell surface, we investigated the outcome Notch controls CXCR4 and SDF-1 in human MM L Mirandola et al on CXCR4-driven migration towards a SDF-1 gradient through a transwell-based chemotaxis assay. Figure 3 shows that Notch blockade lowered the chemotactic response to SDF-1 by 40% on average. In accordance with the limited GSI-XII-mediated CXCR4 decrease observed by quantitative PCR and flow-cytometry analyses, RPMI-8226 cells displayed the lowest effect (30% reduction in mean migration index).
Specific inhibition of Notch-mediated transcription reduces MM cell viability and CXCR4 expression Although GSI-XII is a potent inhibitor of the Notch pathway, it acts indirectly by preventing the g-secretase activity. In addition to Notch, this enzyme has about 50 substrates among type I membrane proteins, including ErbB-4, 37 E-cadherin, 38 colony stimulating factor-1 39 and IL1RII. 40 To evaluate the specific contribution of the Notch pathway to CXCR4 expression, the CSL-dependent transcription was selectively inhibited by SAHM1, a dominant-negative fragment of the coactivator MAML1. 41 In these assays and for the following experiments, we selected OPM-2 cells because they displayed the highest CXCR4 expression levels among the tested MM cell lines (Figure 2 ). OPM-2 cells were treated with escalating concentrations of SAHM1. MTT assay (Figure 4a ) showed that 48-h treatment with 10, 20 and 40 mM SAHM1 decreased cell viability. Further, 40 mM increased the apoptotic rate by more than 50% (Figure 4b) , without significantly affecting cell cycle progression (data not shown). Flow-cytometry analysis (Figure 4c ) confirmed data obtained with GSI-XII treatment: 40 mM SAHM1 significantly reduced CXCR4 þ and SDF-1 þ cell frequency.
Forced Notch1 activation increases CXCR4 þ MM cell frequency
To evaluate if CXCR4 expression is specifically regulated by Notch1, OPM-2 cells were transfected with DE-N1, and analyzed by flow-cytometry 48 h later (Figure 5a ). DE-N1 increased the frequency of CXCR4 þ and SDF-1 þ cells compared with empty pcDNA3.1 (mock). Successful forced Notch1 activation was confirmed by flow-cytometry measurement of active Notch1 levels: Figure 5a shows that DE-N1 increased the frequency of active Notch1 þ cells by three times compared with mock vector.
Notch1 promotes CXCR4 expression by specifically activating its proximal promoter To investigate the specific contribution of Notch1 transcriptional complex in the expression of CXCR4, a dual luciferase assay was Indicated MM cell lines were treated with DMSO or 6 mM GSI-XII for 48 h, then allowed to migrate in response to 100 ng/ml human recombinant SDF-1 in a standard transwell assay. Migration ability was measured by the migration index (Migration Index; see details in Materials and methods). Bars indicate mean migration index calculated from three independent experiments; statistical analysis was performed by analysis of variance and Tukey's post-test (error bars, ± 95% CI; *Po0.05; **Po0.01).
Notch controls CXCR4 and SDF-1 in human MM L Mirandola et al performed in OPM-2 cells. MM cells were transiently transfected by electroporation with the plasmid carrying the CXCR4 promotercontrolled firefly luciferase gene (CXCR4p-FL). The TK promotercontrolled Renilla luciferase (TK-RL) plasmid was used to normalize firefly luciferase activity. Twenty-four hours later, the cells were equally divided in to three wells (0.3 Â 10 6 cells/ml/well) and underwent different treatments for additional 24 h as follows: 6 mM GSI-XII, 40 mM SAHM1 or 0.4% V/V DMSO. Figure 5b shows that the activity of the CXCR4p-FL significantly decreased (by B70%) following GSI-XII or SAHM1 treatment. In a separate set of experiments, OPM-2 cells were cotransfected with the CXCR4p-FL and an expression plasmid encoding the constitutively active form of Notch1 (ICN1) driven by the CMV promoter. 34 Figure 5b shows that the activity of CXCR4p-FL was 34% higher in the presence of ICN1 compared with pCS2 þ mock vector.
The CXCR4/SDF-1 axis is active in cultured MM cell lines and participates in the signaling network activated by Notch receptors We hypothesized that reduced CXCR4 activation could partially account for the biological effects produced by Notch blockade. This hypothesis was acceptable only if CXCR4 was active in culture. Mean values were calculated from three independent experiments (error bars, ± 95% CI; **, two-tailed t-test Po0.01; ***Po0.001). (b) CXCR4 proximal promoter activity was analyzed by a dual luciferase assay after treatment with GSI-XII, SAHM1 or after ICN1 over-expression. Histograms indicate the normalized luciferase activity (firefly luciferase activity/Renilla luciferase activity) driven by the CXCR4 proximal promoter. Mean values were calculated from three independent experiments (error bars, ± 95% CI; *, two-tailed t-test Po0.05; **Po0.01; ***Po0.001).
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To test CXCR4 activation status in OPM-2 cells, the CXCR4/SDF-1 interaction was blocked by using the CXCR4 inhibitor AMD3100 or the SDF-1 blocking antibody for 48 h. A MTT assay was performed to evaluate cell viability: results ( Figure 6 ) showed that blocking CXCR4 activation significantly reduced MM cell viability, indicating that CXCR4 signaling was active in MM cells in culture. This finding prompted us to investigate if CXCR4 hyperstimulation was able to protect MM cells from GSI-XII effects. MM cells were cultured for 48 h with 6 mM GSI-XII, 0.5 mg/ml SDF-1, or both. Figure 7a shows that CXCR4 hyper-stimulation by exogenous SDF-1 was able to rescue the GSI-XII-induced decrease in cell viability. In addition, SDF-1 completely rescued GSI-XIIdependent cell cycle arrest in the G 2 /M phase, increasing the G 0 / G 1 phase. Further, the addition of SDF-1 rescued early and late apoptosis rates induced by GSI-XII (Figure 7b , right column).
Notch blockade in vivo prevents BM invasion by MM cells NOD/SCID xenografts were established using OPM-2 MM cells. As our model of MM spread and bone invasion consisted in intravenous administration of tumor cells, we selected the OPM-2 cell line, which displayed the highest CXCR4 expression levels, resembling BM-homing circulating tumor cells as found in the peripheral blood of MM patients.
14 Cells were administered by intravenous injection, then mice were randomized to receive GSI-XII, or placebo (drug vehicle, DMSO). Cell suspensions prepared from the BM were analyzed by flow-cytometry. Results showed that the BM of GSI-XII-treated mice displayed 82% less CXCR4 þ /active Notch1 þ cells as compared with DMSO-treated animals (Figures 8a and b) , confirming that Notch inhibition reduced CXCR4 expression and suggesting that this reduction may hamper MM cell migration to the BM. Flow-cytometry results were confirmed by using k and l immunoglobulins as independent tumor antigens. Immunohistochemical analysis showed reduced infiltration of k/l þ MM cells in the BM of GSI-XII-treated animals compared with untreated controls (Figure 8c ).
DISCUSSION
Despite effective new therapies have been recently described, MM is still an incurable tumor, 42 mainly because of the interaction between MM cells and the BM milieu, which results in drug resistance 1,2 and diffuse bone disease. [3] [4] [5] [6] As a consequence, MM mortality has not significantly decreased over the last decade. [42] [43] [44] [45] Therefore, there is a need to discover new targetable molecular mechanisms contributing to the progression and the pathogenesis of the disease.
Deregulated Notch signaling has been reported not only to affect MM cell proliferation and apoptosis, but also to influence MM cell interaction with the BM milieu, resulting in increased osteolysis and resistance to chemotherapeutics. 16, 24 In the first part of this work we studied the outcome of Notch withdrawal on MM cell proliferation and apoptosis, which is still object of debate. Our results confirm that Notch blockade hampers MM cell growth according to previous reports. 20, 35, 46 In addition, we show for the first time that g-secretase inhibition by GSI-XII blocks the cell cycle progression in the G 2 /M phase. Although anti-Notch treatments in different cell types frequently affect cell cycle progression by inducing an arrest in the G 0 /G 1 phase, 47 ,48 a similar G 2 /M phase block has already been described following Notch-1 knockdown or g-secretase inhibition in breast cancer. 49 As GSI-XII potentially affects more than 50 g-secretase substrates 37 and reduces the proteasome enzymatic activity, 50 we were prompted to evaluate the specific contribution of the Notch pathway in MM cell growth and apoptosis by using more selective compounds, such as DAPT (GSI-IX), and SAHM1. 41 SAHM1 is a synthetic, cell permeable peptide derived from the Notch coactivator MAML1, and it is able to selectively block Notch transcriptional complex. Results were comparable to those obtained with GSI-XII, confirming that Notch withdrawal inhibits MM cell growth and resistance to apoptosis. However, the efficacy displayed by GSI-XII was higher than that of DAPT and SAHM1, possibly because of the composite inhibitory effects of GSI-XII on the Notch pathway and the proteasome activity. 50 Studies based on Notch-activating strategies in MM reported sometimes controversial results. Two different groups report that Notch stimulation by Jagged1-expressing feeder cells 24 or ICN1 expression 51 negatively affects MM proliferation. Possibly, this is due to a dose-or time-dependent effect of Notch activation. As a matter of fact, by analyzing the early response (24 h) of MM cell lines to Notch activation by Jagged 1-expressing stromal cells, Jundt et al. 20 observed an increase in the S phase. Altogether, independent studies on Notch signaling in MM suggest that Notch activation can be induced by deregulated Notch1, Jagged1 or Jagged2 19, 22 and that it is finely tuned not to exceed a threshold beyond which Notch signaling could be detrimental for MM cells.
The second and most innovative aim of our work was to investigate still unexplored outcomes of Notch signaling in the biology of MM cells, which may result critical for the pathological interactions with the BM. 52 This work stems from the evidence from our and other groups that Notch controls the expression and functions of specific chemokine receptors, including CCR6, 29 CCR7, CCR5, CCR9, 25, 30 CCR4, CCR8, CXCR4 27, 28 and CXCR6. 53 We focused on the CXCR4/ SDF-1 chemokine system, which is clinically relevant in MM: CXCR4 expression is correlated with poor prognosis and disease progression, 8 while elevated SDF-1 serum levels are associated with increased osteolytic bone disease. 9 In addition, Notch and Our results indicate that Notch activation in MM cells positively controls the expression of CXCR4, as well as that of its unique ligand SDF-1 at transcriptional and protein levels.
To better characterize the connection between Notch and CXCR4 in MM cells, we examined whether the CXCR4 promoter was trans-activated by the Notch-dependent transcriptional complex. Luciferase reporter assays revealed that the CXCR4 proximal promoter ( À 310/ þ 53 bp from the transcription start site) was active in cultured MM cells and that its activity could be impaired by GSI-XII and SAHM1 or alternatively enhanced by forced expression of ICN1.
Such interaction between Notch and CXCR4 we describe in MM cells cannot be considered universally valid, as several evidences indicate that the outcome of Notch pathway on the expression and function of CXCR4 is strictly context-dependent. Indeed, Wang et al. 27 found that Notch activation significantly promoted CXCR4 expression during dendritic cell maturation. Consistently with a Notch positive regulation, Notch signaling disruption in BM endothelial progenitor cells led to CXCR4 downregulation. 27 Oppositely, we have previously shown that Notch inhibition did not affect CXCR4 in T-cell acute lymphoblastic leukemia, 25 while Williams et al. 28 described an inverse correlation between CXCR4 and Notch activation through DLL4 in vascular endothelial cells. These evidences indicate that the complex Notch-regulated intracellular signals contribute to control CXCR4 levels in a strictly context-dependent manner. We further confirmed that the CXCR4/SDF-1 axis is a downstream component of the Notch signaling network in MM cell lines. Indeed, forcing CXCR4 activation by adding exogenous SDF-1 to the culture medium allowed MM cells to overcome the G 2 /M phase block and protected from apoptosis induced by GSI-XII. In addition, GSI-XII-treated cells displayed a reduced chemotactic response to SDF-1.
The evidence that Notch was able to control the chemotactic response to SDF-1 in vitro prompted us to validate the effect of Notch withdrawal in vivo. MM cells resulted to be able to infiltrate the BM of xenografted mice with high efficiency, in accordance with our previous report using different MM cell lines and primary MM cells in immune-deficient xenografts. 59 GSI-XII dramatically reduced OPM-2 cells localization in the BM of mice xenografts. This effect was associated with a downregulation of CXCR4 and of the active-Notch1 form in BM-infiltrating MM cells. These in vivo findings strongly suggest that Notch inhibition might reduce MM infiltration in the BM. This is highly relevant, as MM localization in the BM is necessary to establish the known vicious cycle between MM cells and BM stroma, which results in resistance to chemotherapy and bone destruction. 52 To fully understand all the potential outcome of Notch-CXCR4/ SDF-1 interaction in MM, we have also investigated the possible Notch-mediated effect on SDF-1. To our knowledge, this is the first work showing that Notch controls SDF-1 expression. In addition, we provide evidences that CXCR4 signaling is active in OPM-2 cells in culture, as MM cell viability is inhibited by CXCR4 signaling blockade through AMD3100 or anti-SDF-1 antibody, demonstrating that a CXCR4 activation loop exists in this cell line and depends on Notch signaling. Although SDF-1 levels in the medium of cultured OPM-2 cells were comparable to those of the other cell lines under evaluation (KMS-12 and RPMI-8226) and MM plasma cells from patients are reported to produce significant amounts of SDF-1, 9 it is still unclear whether an autocrine CXCR4/SDF-1 loop is a common feature of the disease or of a subset of MM cells. However, our results are consistent with the evidence from other groups, indicating that BM-infiltrating MM cells could be a significant source of SDF-1 in MM patients, 9 in addition to endothelial cells, stromal cells and immature osteoblasts. 10 Moreover, our work suggests that Notch withdrawal can affect the autonomous SDF-1 production by MM cells.
Collectively, our results depict this scenario: Notch might have a role in MM progression by controlling the CXCR4/SDF-1 system and therefore the biological effects mediated by this chemokine system, such as the localization and retention of MM cells in the BM, the occurrence of resistance to therapy and bone disease, which are well known causes of mortality and morbidity in patients. 2, 4 If confirmed by clinical studies on MM patients, these data could provide a rationale for novel therapeutic approaches. Therefore, we believe that a Notch-tailored therapy, possibly in association with available CXCR4-targeted drugs, 32, 56 could be instrumental to improve the outcome of conventional front-line treatments.
